Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study

Pear Therapeutics announced the first patient dosed in part II of the first clinical study evaluating Pear-006, a digital therapeutic product candidate for addressing depressive symptoms in Multiple Sclerosis (MS).